Caxton Associates LLP Buys New Position in Danaher Corporation $DHR

Caxton Associates LLP purchased a new position in shares of Danaher Corporation (NYSE:DHR) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 5,612 shares of the conglomerate’s stock, valued at approximately $1,064,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Elevated Capital Advisors LLC acquired a new stake in shares of Danaher in the fourth quarter valued at approximately $26,000. Hilton Head Capital Partners LLC acquired a new position in shares of Danaher in the 4th quarter valued at $27,000. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Danaher by 71.6% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock valued at $29,000 after acquiring an additional 53 shares during the period. JPL Wealth Management LLC purchased a new stake in Danaher in the 3rd quarter valued at $25,000. Finally, Main Street Group LTD purchased a new stake in Danaher in the 1st quarter valued at $25,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $191.87 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The firm has a market cap of $134.88 billion, a price-to-earnings ratio of 34.08, a price-to-earnings-growth ratio of 2.38 and a beta of 0.79. The firm’s fifty day moving average price is $185.64 and its 200 day moving average price is $196.76. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 21st. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter in the prior year, the firm earned $0.77 EPS. Danaher’s quarterly revenue was up 5.5% on a year-over-year basis. On average, sell-side analysts expect that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Friday, June 26th. Danaher’s payout ratio is 28.42%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. UBS Group lowered their price objective on shares of Danaher from $270.00 to $250.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. Stifel Nicolaus reduced their target price on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a report on Wednesday. Piper Sandler initiated coverage on shares of Danaher in a research note on Thursday, June 11th. They set a “neutral” rating and a $200.00 target price for the company. Rothschild & Co Redburn set a $205.00 price target on Danaher in a report on Friday, April 17th. Finally, Robert W. Baird dropped their price target on Danaher from $251.00 to $249.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $228.91.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR)
• Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
• Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
• Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
• Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.